And so, GLP-1 therapies improve weight, blood sugar and lipid profiles, and some have demonstrated cardiovascular event reduction in high-risk populations, which makes them particularly relevant for patients with RA who also have diabetes or obesity-related cardiovascular risk
patients in GLP-1 telehealth obesity programs as of Q1 2026
Size Quantity $44.99 $44.99 In stock Bundle & Save Best Sellers Order within 27h 46m to ship tomorrow, Aug 3 Each 3 mL vial contains 10mg lyophilized powder for controlled laboratory preparation workflows
Active Ingredient Cagrilintide lyophilized peptide (2.5mg, 5mg, 10mg) Strength Tier Research-grade only Time to Results Not applicable (research use) Sun Sensitivity Not applicable research peptide Regulatory Status Research use only not for human consumption Cycling / Off Period Per study protocol not for human cycling Best For Licensed laboratory researchers studying amylin-analogue pharmacology, satiety signaling, and appetite-regulation pathways in controlled in-vitro or preclinical settings
According to the drugs prescribing information, gastrointestinal side effects occur most often during the initial dose-escalation phase (the first several weeks when your dosage is gradually being increased)
10.4236/ijcm.2020.1110049 56